Johnson & Johnson Reports Q1 2026 Revenue of $24.06 Billion, Raises Full-Year Guidance

On April 14, 2026, Johnson & Johnson released its first-quarter financial report for the fiscal year 2026. The group's total sales reached $24.062 billion (equivalent to RMB 164.2 billion), representing a year-on-year increase of 9.9%. Among this, the MedTech sector performed particularly outstandingly, with sales reaching $8.636 billion, a year-on-year increase of 7.7% and operational growth of 4.7%, becoming one of the core engines of the group's growth.

Johnson & Johnson Raises Full-Year Outlook Based on Strong Performance, Forecasting Midpoint Sales of $100.8 Billion, Up 7.0% Year-over-Year, and Adjusted Earnings Per Share of $11.55, Up 7.1%.

By region, sales in the U.S. market reached $4.459 billion, growing by 5.9%, while international markets hit $4.177 billion, surging by 9.7%. Currency fluctuations contributed a positive 3.1 percentage points, demonstrating the risk-resistance capability of Johnson & Johnson’s globalized layout. In terms of business structure, Johnson & Johnson MedTech has formed a "four-wheel drive" pattern: "cardiovascular as the core, orthopedics as the foundation, with rapid growth in surgery and ophthalmology."

Cardiovascular business becomes the first growth curve. Electrophysiology continues double-digit growth, with the newly launched VARIPULSE Pro pulsed field ablation system in Europe significantly reducing procedure time; Abiomed's Impella series increases penetration in scenarios such as cardiogenic shock and high-risk PCI; Shockwave experiences explosive growth in peripheral and coronary IVL fields, becoming the "gold standard" for complex calcified lesions.

Orthopedic business returned to steady growth after restructuring, with trauma business showing the most outstanding performance; joint business growing faster in international markets than in the U.S.; spine and sports medicine steadily advancing structural optimization. Overall focus remains on high value-added areas.

Surgical business transitions to minimally invasive comprehensive solutions, maintaining leadership in premium staplers, ultrasonic scalpels, and energy platforms, while strengthening robotic collaboration and digital surgical systems. In ophthalmology, the TECNIS PureSee new intraocular lens received FDA approval, reinforcing its leading position in premium refractive lenses.